Kristi Rosa

Articles

Tipifarnib Gets Breakthrough Therapy Designation for HRAS-Mutated HNSCC

February 25, 2021

The FDA has granted a breakthrough therapy designation to tipifarnib for use in patients with recurrent or metastatic HRAS-mutated head and neck squamous cell carcinoma with variant allele frequency of 20% or higher following progressive disease on platinum-based chemotherapy.

Vicineum Granted Priority Review for High-Risk, BCG-Unresponsive Bladder Cancer

February 18, 2021

The FDA has accepted and granted a priority review designation to the biologics license application for Vicineum for use in patients with high-risk Bacillus Calmette-Guérin–unresponsive non–muscle invasive bladder cancer.

FDA Approves Cemiplimab for Advanced Basal Cell Carcinoma

February 09, 2021

The FDA approved cemiplimab-rwlc as the first immunotherapy for use in patients with advanced basal cell carcinoma that has previously been treated with a hedgehog pathway inhibitor (HHI) or for whom a HHI is not appropriate.

Liso-Cel Approved for Refractory Large B-Cell Lymphoma

February 06, 2021

The FDA has approved lisocabtagene maraleucel (Breyanzi) for the treatment of adult patients with certain types of large B-cell lymphoma who have not responded to, or who have relapsed after, at least 2 other types of systemic treatment.

Cancer Drugs Spark Hope in Combatting COVID-19

February 05, 2021

In response to the novel coronavirus disease 2019 (COVID-19) pandemic, investigators around the world channeled their efforts into acquiring a better understanding of the virus so that they could rapidly identify any weapons that may be used in the fight against its spread; this included turning to tried-and-true cancer drugs to see whether they could be repurposed to address this pressing need.